Muscular Dystrophy Treatment Market Insight Report 2021
Muscular Dystrophy is characterized by a collection of muscle-wasting conditions.
The disorder is caused by genetic mutations which interfere with the production of
muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a
genetic disease, consequently, the chance of an individual developing a disease
increases with a history of muscular dystrophy in the family.
The key players operating the global Muscular Dystrophy Treatment Market
include Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical,
Sarepta Therapeutics and Eli Lilly. The approval and launch of oral corticosteroid
Emflaza in 2017, has been found highly effective in patients to regain strength and
restore their ability to walk. The other vendors include Acceleron Pharma, Capricor
Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer.
Read More@ https://bit.ly/3b39ztB